

Attorney Docket No. 5694.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Flodgaard et al.

Serial No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: J. Roark

Confirmation No: 2707

For: Inhibition Of Bradykinin Release

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, DC 20231

On October 11, 2001.

Cheryl H. Agis  
(name of person mailing paper)

Cheryl H. Agis  
(signature of person mailing paper)

PATENT

#11/a

Harry  
Oct. 2001

TECH CENTER 1600/2900

OCT 19 2001

RECEIVED

640/644



Attorney Docket No. 5694.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

*[Handwritten signature]*

In re Application of: Flodgaard et al.

Serial No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: J. Roark

Confirmation No: 2707

For: Inhibition Of Bradykinin Release

RECEIVED  
OCT 19 2001  
TECH CENTER 1600/2900

AMENDMENT FEE TRANSMITTAL

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed April 12, 2001.

It is respectfully requested that the time for response to the Office Action dated

10/22/2001 01:11:17 00000000 14-147 00000000 14-147  
April 12, 2001 be extended for a period of 3 months from July 12, 2001 to September 12, 2001.

01 FC:117 328.00 CH  
02 FC:103 18.00 CH  
The required fee for the extension is estimated to be \$920.

The fee for claims has been calculated as shown below:

Total:  $10 - 42 = 0 \times 18 = \$0$


Independent:  $1 - 12 = 0 \times 84 = \$0$

No additional claims fee is required.

In the event that an extension of time is required, Applicant(s) hereby petition(s) for such extension of time. The Assistant Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

Please charge the required extension and claims fees, estimated to be \$920, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,



Date: October 11, 2001

Cheryl H. Agis, Reg. No. 34,086  
Outside Counsel for Novo Nordisk  
of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

**\*23650\***

**23650**

PATENT TRADEMARK OFFICE

Attorney Docket No.: 09/559,764-200-US



*Handwritten:* \$111a  
Harry  
PATENT  
Oct. 20, 01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Flodgaard et al.

Application No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: J. Roark

For: Inhibition Of Bradykinin Release

AMENDMENT UNDER 37 C.F.R. 1.121

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Office Action dated April 12, 2001, please consider the following amendments and remarks.

RECEIVED  
OCT 19 2001  
TECH CENTER 1600/2900

IN THE CLAIMS

Please cancel claims 1-6 and 12-14. Please add new claims 43-52:

*Handwritten:* a

43. A method for preventing or treating a disorder resulting from release of bradykinin and alterations in endothelial cell permeability in a mammal, wherein said mammal produces heparin binding protein (HBP) that is (i) proteolytically inactive; (ii) stored in the azurophil granules of polymorphonuclear leukocytes and (iii) a chemoattractant for monocytes and/or activates monocytes, wherein said heparin binding protein interacts with kininogen resulting in release of bradykinin and said heparin-binding protein induces alterations in endothelial cell permeability in said mammal, said method comprising administering to said mammal in need thereof, an amount of an anti-heparin binding protein